<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262000</url>
  </required_header>
  <id_info>
    <org_study_id>WVU010513</org_study_id>
    <nct_id>NCT02262000</nct_id>
  </id_info>
  <brief_title>Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer</brief_title>
  <acronym>SABR</acronym>
  <official_title>A Phase II Clinical Trial of Image Guided Stereotactic Ablative Radiotherapy (SABR) for T2 and Microscopic T3 (PL3), N0,M0 Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help researchers learn about the best dose of radiation to be used when
      treating large early stage non-small cell lung cancer (NSCLC) with a treatment called
      stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC
      show positive response. But, for large early stage NSCLC it may be better to give different
      SABR doses than what is used in routine early stage NSCLC treatment. It is not understood
      which dose is best for treating large early stage NSCLC. Therefore, this study can help
      researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can
      increase the chance of cure for large early stage NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment Plan:

      7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT.

        -  Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations
           where dose constraints for organs at risk can be EASILY met while optimal PTV coverage
           is achieved; but the 7.5 Gy x 10 daily fractions schedule is preferred.

        -  All doses are prescribed to the tumor periphery.

      For this protocol, patients will be followed only up to 2 years post radiation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate (absence of local progression) using SABR for treatment of NSCLC</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the 2-year regional, and distant metastasis rates, progression-free survival (PFS), local progression free survival (L-PFS), overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A - 7.5 Gy x 10 daily fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - 12 Gy x 5 daily fractions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image Guided Stereotatic Ablative Radiotherapy</intervention_name>
    <arm_group_label>A - 7.5 Gy x 10 daily fractions</arm_group_label>
    <arm_group_label>B - 12 Gy x 5 daily fractions</arm_group_label>
    <other_name>SABR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-Small Cell Lung Cancer

          -  T2N0M0 or T3(PL3)N0M0 or Locally recurrent â‰¤ 7 cm

          -  Surgically inoperable

          -  ECOG Performance 0-2

        Exclusion Criteria:

          -  Pacemaker on the same side of the tumor

          -  Pregnant

          -  Infection that requires IV antibiotics

          -  Concomitant or adjuvant anti-neoplastic chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Mattes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University Hospitals Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Surgically inoperable</keyword>
  <keyword>Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

